From GlobeNewswire: 2025-02-10 16:05:00

iBio, Inc. reported financial results for Q2 2025, highlighting key Board appointments and advancements in its preclinical pipeline. The company in-licensed IBIO-600 for cardiometabolic and obesity programs and initiated a bispecific antibody program targeting myostatin/activin A. Cash, cash equivalents, and restricted cash totaled $7.2 million as of Dec. 31, 2024.

In Q2 2025, iBio reported revenue of $0.2 million from services to a collaborative partner. R&D and G&A expenses totaled approximately $4.6 million, resulting in a net loss of $4.4 million from continuing operations. Cash, cash equivalents, and restricted cash were $7.2 million as of Dec. 31, 2024.

iBio, Inc. is a biotech company developing biopharmaceuticals for various diseases using AI and advanced computational biology. The company aims to create breakthrough antibody treatments for unmet medical needs. With a focus on cardiometabolic diseases, obesity, and cancer, iBio is dedicated to transforming drug discovery and advancing precision medicine.



Read more at GlobeNewswire:: iBio Reports Fiscal Second Quarter 2025 Financial Results